Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Bristol-Myers Squibb Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Bristol-Myers Squibb steigerte seine Gewinne mit einer durchschnittlichen jährlichen Rate von 12.8%, während die Branche Pharmaceuticals Gewinne von wachsend um 10.9% jährlich. Der Umsatz ist gewachsen mit einer durchschnittlichen Rate von 11.9% pro Jahr.

Wichtige Informationen

12.8%

Wachstumsrate der Gewinne

7.5%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	12.4%
Wachstumsrate der Einnahmen	11.9%
Eigenkapitalrendite	-37.1%
Netto-Marge	-13.5%
Nächste Ertragsaktualisierung	26 Jul 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Bristol-Myers Squibb Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

BASE:BMY Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	45,534	-6,148	7,884	9,252
31 Dec 23	45,006	8,025	7,678	9,112
30 Sep 23	44,935	8,285	7,874	9,146
30 Jun 23	45,187	7,963	7,784	9,226
31 Mar 23	45,848	7,311	7,636	9,274
31 Dec 22	46,159	6,327	7,703	9,201
30 Sep 22	46,738	6,677	7,785	9,209
30 Jun 22	47,144	6,617	7,724	9,319
31 Mar 22	46,960	6,251	7,808	9,266
31 Dec 21	46,385	6,994	7,655	10,195
30 Sep 21	45,468	-5,405	7,747	9,371
30 Jun 21	44,384	-5,079	7,712	9,279
31 Mar 21	42,810	-6,219	7,442	9,182
31 Dec 20	42,518	-9,015	7,618	10,048
30 Sep 20	39,395	-44	6,626	8,655
30 Jun 20	34,862	-563	5,921	7,737
31 Mar 20	31,006	954	5,399	6,868
31 Dec 19	26,145	3,439	4,969	6,066
30 Sep 19	24,173	5,655	4,549	5,281
30 Jun 19	23,857	6,203	4,568	5,185
31 Mar 19	23,288	5,144	4,585	5,245
31 Dec 18	22,561	4,920	4,523	6,253
30 Sep 18	22,037	1,432	4,230	5,184
30 Jun 18	21,600	376	4,327	5,109
31 Mar 18	21,040	919	4,438	4,958
31 Dec 17	20,776	1,007	4,749	6,085
30 Sep 17	20,570	4,229	4,896	4,697
30 Jun 17	20,238	4,586	4,877	4,589
31 Mar 17	19,965	4,836	4,929	4,513
31 Dec 16	19,427	4,457	4,815	4,477
30 Sep 16	18,471	3,366	4,947	4,366
30 Jun 16	17,618	2,870	4,977	4,310
31 Mar 16	16,910	1,574	4,871	4,181
31 Dec 15	16,560	1,565	4,831	4,037
30 Sep 15	16,531	1,775	4,697	4,001
30 Jun 15	16,383	1,790	4,625	3,896
31 Mar 15	16,109	2,253	4,628	3,869
31 Dec 14	15,879	2,004	4,717	3,913
30 Sep 14	16,062	2,717	4,666	3,715
30 Jun 14	16,206	2,688	4,734	3,690
31 Mar 14	16,365	2,891	4,858	3,683
31 Dec 13	16,385	2,563	4,923	3,715
30 Sep 13	16,135	2,762	4,964	3,791
30 Jun 13	15,806	1,360	4,962	3,801

Qualität der Erträge: BMY ist derzeit unrentabel.

Wachsende Gewinnspanne: BMY ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: BMY ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 12.8% pro Jahr reduziert.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von BMY verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: BMY ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (7.3%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: BMY hat eine negative Eigenkapitalrendite (-37.07%), da es derzeit unrentabel ist.

Bristol-Myers Squibb Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol-Myers Squibb Company to Report Q3, 2023 Results on Oct 26, 2023

Recent updates

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 Commands Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes At Ash 2023

Bristol-Myers Squibb Company Presents New Data At ASH 2023 Demonstrating Clinical Benefit Across B-Cell Malignancies with Breyanzi as A Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary

Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb Appoints Christopher Boerner as Chief Executive Officer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 Checkmate -77T Trial

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Early Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types At Esmo2023

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company to Report Q3, 2023 Results on Oct 26, 2023

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on November 1, 2023

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bristol Myers Squibb Announces New Long-Term Follow-Up Results from Two Phase 3 Studies Evaluating CAMZYOS (Mavacamten)

The Bristol Myers Squibb-Pfizer Announces Results from ATHENS

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren